Anand N, Kanwar RK, Dubey ML, et al. Drug Des Devel Ther. 2015;9:3821-3835.
The authors have advised due to an error that occurred inadvertently at the time of
figure assembly, the representative image for 40 µg Holo form sample, in Figure 1A
was included as a duplicate image of 20 µg Apo form sample. In addition, for the untreated
sample, the representative image of the same microscopic field was included twice.
It is also noted in the abbreviations list "BLf Fe, bovine apolactoferrin" should
read "BLf Apo, bovine apolactoferrin".
The correct Figure 1 is shown below. These changes do not affect the conclusions of
the article in any way. The authors apologize for this unintentional human error.
(A) Giemsa stain microscopy of red blood cells treated with different forms of lactoferrin
at different concentrations (100×) and the untreated group. This experiment was repeated
in triplicate. Morphological characteristics, ie, shape, size, and diameter, were
the same in the different treated red blood cells compared with the untreated group.
(B) Morphometric analysis of RBCs treated for 48 hours with the different proteins
at a concentration of 40 μg/mL. No significant difference was found between the treated
and untreated groups.
Abbreviations: BLf, bovine lactoferrin; BLf Apo, bovine apolactoferrin; BLf Fe, iron-saturated
bovine lactoferrin; BuLf, buffalo lactoferrin; BuLf Apo, buffalo apolactoferrin; BuLf
Fe, iron-saturated buffalo lactoferrin; RBCs, red blood cells.